Enteric encapsulation of ancrod for oral administration

Details Enteric encapsulation of ancrod for oral administration Enteric encapsulation of ancrod for oral administration

1986-04-28

1988-03-08

Rosen, Sam

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

514 2, A61K 3558

Patent

active

047298936

ABSTRACT:
Disclosed is a pharmaceutically effective agent and method of use, comprising ancrod which has been incubated with neuraminidase. The neuraminidase-treated ancrod (NTA) can be substituted for ancrod in ancrod therapy, when immunological resistance to the latter has become manifest. Conversely, NTA can be administered initially, and ancrod substituted therefor after NTA resistance becomes manifest. In a second embodiment, the efficacy of ancrod treatment is improved by enterically coated oral administration of native ancrod.

REFERENCES:
patent: 4585653 (1986-04-01), Williams
Bell-CRC Handbook Ser. Clin. Lab. Sci., Sect. I, vol. 3 (1980) pp. 301, 306 & 311.

Affiliated with

Also associated with

Rating

Enteric encapsulation of ancrod for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enteric encapsulation of ancrod for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enteric encapsulation of ancrod for oral administration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-230803